Silence Therapeutics Plc ADR (SLN) Stock Price, Quote & News

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3457 6900

Website: www.silence-therapeutics.com

Address:

72 Hammersmith Road, London, United Kingdom

AMWG42isback Jun. 27 at 3:09 PM

$SLN no walls till 7.00. This has to test 6.14 again, then 6.30, and needs to find support around 6.00 to leg up anymore.

0 · Reply

AMWG42isback Jun. 26 at 1:33 PM

$SLN wow

0 · Reply

AMWG42isback Jun. 25 at 1:41 PM

$SLN and just like that, all those gains are gone with 1 fuckin trade

0 · Reply

LIGator Jun. 24 at 7:31 PM

$SLN has not closed above $6 since February. Today could be the day. The VWAP Is $6.12 so that would be a great close. Next goal is the 200 average above $8. The January 2026 $5 calls are waking up.

0 · Reply

AMWG42isback Jun. 24 at 3:29 PM

$SLN

0 · Reply

AMWG42isback Jun. 24 at 2:16 PM

$SLN needs to break 6.14 otherwise back down we go

0 · Reply

AMWG42isback Jun. 23 at 6:38 PM

$SLN someone wants this below 6.00. The manip is wild

0 · Reply

AMWG42isback Jun. 23 at 2:39 PM

$SLN denied at 6.14 as predicted

0 · Reply

AMWG42isback Jun. 23 at 1:52 PM

$SLN there is a wall at 6.00$ and it’s absolutely fucking us

0 · Reply

AMWG42isback Jun. 20 at 8:41 PM

$SLN time to retest the 6.00-6.14 range again

0 · Reply

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

May 8, 2025, 8:00 AM EDT - 7 weeks ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025, 7:45 AM EDT - 7 weeks ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Mar 5, 2025, 8:00 AM EST - 4 months ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Feb 28, 2025, 11:59 AM EST - 4 months ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:30 AM EST - 4 months ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 8:00 AM EST - 4 months ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Dec 18, 2024, 7:46 AM EST - 6 months ago

Top 3 Health Care Stocks That May Explode In Q4

MODV OLMA

Dec 9, 2024, 7:30 AM EST - 7 months ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Nov 26, 2024, 8:00 AM EST - 7 months ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:34 PM EST - 7 months ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Nov 19, 2024, 7:52 AM EST - 7 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN

Nov 18, 2024, 2:30 PM EST - 7 months ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 14, 2024, 8:00 AM EST - 8 months ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 8 months ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Sep 8, 2024, 9:13 AM EDT - 10 months ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Sep 5, 2024, 2:18 PM EDT - 10 months ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Aug 27, 2024, 8:00 AM EDT - 10 months ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 15, 2024, 7:30 AM EDT - 11 months ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 21, 2024, 2:31 PM EDT - 1 year ago

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

May 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 8, 2024, 11:48 AM EDT - 1 year ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Mar 13, 2024, 10:01 AM EDT - 1 year ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Feb 28, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 24, 2024, 8:53 PM EST - 1 year ago

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Feb 23, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 5, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Jan 31, 2024, 7:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 1, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Nov 14, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in September Investor Conferences

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

Jul 14, 2023, 7:15 PM EDT - 2 years ago

Silence Therapeutics: No Reason For It To Fall So Much

Jul 11, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

May 31, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 16, 2023, 4:00 PM EDT - 2 years ago

Silence Therapeutics Reports First Quarter 2023 Results

May 4, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

AMWG42isback Jun. 27 at 3:09 PM

$SLN no walls till 7.00. This has to test 6.14 again, then 6.30, and needs to find support around 6.00 to leg up anymore.

0 · Reply

AMWG42isback Jun. 26 at 1:33 PM

$SLN wow

0 · Reply

AMWG42isback Jun. 25 at 1:41 PM

$SLN and just like that, all those gains are gone with 1 fuckin trade

0 · Reply

LIGator Jun. 24 at 7:31 PM

$SLN has not closed above $6 since February. Today could be the day. The VWAP Is $6.12 so that would be a great close. Next goal is the 200 average above $8. The January 2026 $5 calls are waking up.

0 · Reply

AMWG42isback Jun. 24 at 3:29 PM

$SLN

0 · Reply

AMWG42isback Jun. 24 at 2:16 PM

$SLN needs to break 6.14 otherwise back down we go

0 · Reply

AMWG42isback Jun. 23 at 6:38 PM

$SLN someone wants this below 6.00. The manip is wild

0 · Reply

AMWG42isback Jun. 23 at 2:39 PM

$SLN denied at 6.14 as predicted

0 · Reply

AMWG42isback Jun. 23 at 1:52 PM

$SLN there is a wall at 6.00$ and it’s absolutely fucking us

0 · Reply

AMWG42isback Jun. 20 at 8:41 PM

$SLN time to retest the 6.00-6.14 range again

0 · Reply

Laurapicksright Jun. 16 at 5:20 PM

$SLNH Massive gap to fillll BTC data center playyy with partnerships with $HPE $NVDA should get found off $SLN $DWSN 😍😍😍

0 · Reply

AMWG42isback Jun. 13 at 1:21 PM

$SLN https://www.marketscreener.com/quote/stock/SILENCE-THERAPEUTICS-PLC-111895683/news/Silence-Therapeutics-Says-Diversiran-Profile-Remains-Compelling-in-Updated-Data-50229575/

0 · Reply

AMWG42isback Jun. 13 at 1:20 PM

$SLN https://www.businesswire.com/news/home/20250612873071/en/Silence-Therapeutics-Presents-Additional-Phase-1-Data-Highlighting-Promise-of-Divesiran-as-the-Potential-First-in-Class-siRNA-Treatment-for-Polycythemia-Vera

0 · Reply

JarvisFlow Jun. 13 at 11:30 AM

HC Wainwright & Co. has updated their rating for Silence Therapeutics ( $SLN ) to Buy with a price target of 75.

0 · Reply

JarvisFlow Jun. 13 at 11:00 AM

Chardan Capital has updated their rating for Silence Therapeutics ( $SLN ) to Buy with a price target of 35.

0 · Reply

AMWG42isback Jun. 11 at 8:20 PM

$SLN 140k volume in last 5 minutes? Something’s not passing the sniff test with this stock.

0 · Reply

AMWG42isback Jun. 11 at 4:25 PM

$SLN

0 · Reply

AMWG42isback Jun. 10 at 4:56 PM

$SLN

0 · Reply

BioForGood Jun. 9 at 5:21 PM

$SLN SLN is quite undervalued and will go back to $10 soon

0 · Reply

AMWG42isback Jun. 6 at 2:53 PM

$SLN well that was short lived lol

1 · Reply

AMWG42isback Jun. 4 at 7:23 PM

$SLN days almost over and not even 50K volume

0 · Reply

LIGator Jun. 3 at 8:06 PM

$SLN I was having a lot more fun last week. Painfully waiting for double digits.

0 · Reply

Market Cap	173.30M
Revenue (ttm)	43.26M
Net Income (ttm)	-45.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-104.74%
Debt to Equity Ratio	0.00

Volume	141,000
Avg Vol	178,358
Day's Range	N/A - N/A
Shares Out	29.93M
Stochastic %K	61%
Beta	1.41
Analysts	Strong Sell
Price Target	$32.17